The Orthobiologics Market is projected to reach USD 6.06 Billion by 2022 from USD 4.66 Billion in 2017, at a CAGR of 5.4% during the forecast period.
- Advertising -
Browse 60 Market Data Tables and 38 Figures spread through 159 Pages and in-depth TOC on "Orthobiologics Market"
The report analyzes and studies the major drivers, restraints, opportunities, and challenges of the Orthobiologics Market in North America, Europe, Asia Pacific, and the Rest of the World (RoW). Factors such as rising burden of orthopedic injuries; increasing incidence of sports injuries and road accidents; increasing incidence of spinal fusion surgeries; risk factors associated with increasing aging population, obesity rate, & high incidence of musculoskeletal disorders; and growing patient preference for minimally invasive procedures are driving the Orthobiologics Market.
However, high cost pertaining to orthobiologics based treatment is the major factor restraining the market growth to a certain extent.
Download PDF Brochure: www.marketsandmarkets.com/pdfdownl…m_campaign=PaidPR
Based on product, the viscosupplementation products segment is estimated account for the largest segment of the market in 2017
On the basis of product, the Orthobiologics Market is segmented into allografts, synthetic orthobiologics, plasma-rich protein (PRP), bone marrow aspirate concentrate (BMAC), demineralized bone matrices (DBM), bone morphogenic protein (BMP), and viscosupplementation products.
- Advertising -
The viscosupplementation products segment is expected to account for largest share of the Orthobiologics Market in 2017. The large share of this segment can be attributed to the increasing incidence of osteoarthritis of the knee and hip joints among the baby boomer population and lower cost of viscosupplementations.
Based on application, the osteoarthritis and degenerative arthritis segment expected to account for the largest share of the market in 2017
Based on application, the Orthobiologics Market is segmented into fracture recovery, osteoarthritis & degenerative arthritis, spinal fusion, soft tissue injuries, and maxillofacial & dental applications. The osteoarthritis and degenerative arthritis segment is estimated to command the largest share of the global Orthobiologics Market in 2017.
The large share of this segment is mainly due to factors such as the significant rise in target patient population across major markets, rising public awareness related to clinical side effects associated with oral medications for pain management, clinical advancements in OA management methodologies, robust healthcare infrastructure & facilities for specific joint replacement surgeries across major markets, and growing clinical evidence validating the efficacy of biologics in OA treatment.
Talk To Our Research Analysts: www.marketsandmarkets.com/speaktoa…m_campaign=PaidPR
In 2017, North America is expected to account for the largest share of the Orthobiologics Market
Geographically, the Orthobiologics Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to account for the largest share of the global Orthobiologics Market in 2017.
The growth of this region is attributed to rising incidence of orthopedic and spinal disorders; increasing geriatric population coupled with obesity; growing population exposure to key risk factors; rising number of spinal fusion surgeries and rising patient preference for minimally invasive orthopedic therapies over invasive grafting procedures; and growing physician and patient awareness about the newly introduced treatment procedures and technologies.
The major players in the market are DePuy Synthes, Medtronic, Stryker, Zimmer Biomet, Harvest Technologies, Globus Medical, Orthofix International, RTI Surgical, K2M Group, Kuros Biosciences, Bioventus, NuVasive, SeaSpine, Arthrex, and Xtant Medical.
Category: Market Research Publishers and RetailersCompany profile: MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth ...
For more information: